Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models
Robert Cavanagh, Patricia Monteiro, Cara Moloney, Alessandra Travanut, Fatemeh Mehradnia, Vincenzo Taresco, Ruman Rahman, Stewart G. Martin, Anna M. Grabowska, Marianne Ashford, Cameron Alexander
Abstract
Combinations of the topoisomerase II inhibitor doxorubicin and the poly (ADP-ribose) polymerase inhibitor olaparib offer potential drug–drug synergy for treatment of triple negative breast cancers (TNBC) both in free drug form and when delivered by oxidation-responsive nanoparticles.
Topics & Concepts
Triple-negative breast cancerDoxorubicinOlaparibBreast cancerChemistryDrug deliveryDrugCancer researchTargeted drug deliveryPharmacologyCancerMedicineChemotherapyBiochemistryInternal medicineEnzymePoly ADP ribose polymeraseOrganic chemistryPolymerasePARP inhibition in cancer therapyNanoparticle-Based Drug DeliveryCell death mechanisms and regulation